Thank you, Justin. Today, I'll begin with an overview of our first quarter financial results, then I'll discuss portfolio performance before concluding with detail on our balance sheet positioning. Total investment income for the first quarter was $55 million, generally in line with prior quarter due primarily to a higher average portfolio balance, offset by lower weighted average yields on the portfolio and lower dividends from Credit Fund II. Total expenses of $33 million increased versus prior quarter, primarily as a result of higher interest expense from a higher average outstanding debt balance driven by growth in the portfolio. The result was GAAP net investment income for the first quarter of $21 million or $0.40 per share and adjusted net investment income per share of $0.41, which excludes the amortization of the purchase price premium of the CSL III merger and the purchase price discount associated with the consolidation of Credit Fund II. Now excluding the additional $0.02 per share of income from last quarter's one-time incremental dividends from Credit Fund II, which cleared the spillover income in NAV vehicle, this quarter's earnings represent about a $0.04 per share decline from the prior quarter, attributable to tighter yields from the combination of lower new issue spreads, lower base rates or pricing of existing loans and a modest uptick in non-accruals as well as the repayment at the end of last quarter of our lower-cost bonds that were issued in a low interest rate environment. So given the timing of the merger closed in the last week of March, Q1 earnings primarily represent income generated from pre-combination standalone CGBD. The earnings power of the combined portfolio will be reflected in Q2 earnings. And on a per share basis, we expect NII to remain in the same range as Q1. Our Board of Directors declared a dividend for the second quarter of 2025 at a level of $0.40 per share, equal to our base dividend, which is payable to stockholders of record as the close of business on June 30. This dividend level represents an attractive yield of about 11% based on the recent share price. In addition, we have $0.85 per share of spillover income generated over the last five years. So we feel comfortable in our ability to maintain the base dividend. On valuations, our total aggregate realized and unrealized net loss was about $8 million for the quarter, partially attributable to a markdown on Maverick, which we added to non-accrual during the quarter. This was partially offset by the successful exit of SPF at par and markups in the value of our equity positions in SPF and Bayside, formerly known as Derm Growth and ProPT, respectively. Turning to credit performance, we continue to see overall stability in credit quality across the portfolio with some underperformance in a handful of names, and we're continuing to actively assess each portfolio of companies tariff risk exposure. For most of our borrowers, this is not the first time they'll be reassessing supply chains. Should we feel comfortable that the direct impact may be somewhat limited, outside of the broader risk of a slowdown in overall economic growth. For businesses that may not be directly impacted, including those in the US services sectors, we're focused on evaluating the potential secondary effects of reduced demand as various companies may face higher costs. On the metrics, the risk rating distribution improved in the quarter with the addition of the CSO3 assets, which were substantially risk rated two. Although non-accruals increased to 1.6% of total investments at fair value. We continue to work closely with both sponsors and borrowers to position our portfolio of companies for improved financial performance. And while our non-accrual rates may fluctuate from period-to-period, we're confident in our ability to leverage the broader Carlyle network to achieve maximum recoveries for underperforming borrowers. Moving to the credit funds. I previewed last quarter, we've been focused on optimizing our joint ventures over the last number of quarters. In February, we consolidated Credit Fund II onto CGBD's balance sheet to address the static nature of that vehicle. Following this transaction, we turned our focus on optimizing Credit Fund I by extending the investment period by three years and closing a new credit facility with overall more attractive terms and economics, which should materially improve ROE at that vehicle. Both of these transactions increased our non-qualifying asset capacity thereby providing greater flexibility going forward for both complementary transactions and other strategic partnerships. I'll finish by touching on our financing facilities and leverage. We continue to improve our capital structure in early 2025. In March, we upsized and extended our primary revolving credit facility, increasing total commitments by $145 million to $935 million in total. Further increasing our debt capacity upon closing the merger, CGBD assumed the $250 million CSL III credit facility. Also in connection with the closing of the merger, Carlyle exchanged its preferred stock for common stock at net asset value per share, instead of the latest conversion price of $8.87 per share. And this eliminated the historical overhang from the potential dilutive impact of the preferred equity on both NAV and NII. Finally, at the end of March, we entered into an equity distribution agreement, enabling us to raise additional dry powder through an at-the-market equity offering program. At quarter end, statutory leverage was about 1 turn providing capacity to deploy capital into attractive opportunities. With that, I'll turn the call back over to Justin.